BASF Expands its Capacity for Specialty Amines at its Verbund site in Ludwigshafen
BASF is significantly expanding its production capacity for about 20 specialty amines at its Verbund site in Ludwigshafen. The company will therefore invest a double-digit million euro amount in expanding current production facilities, which are planned to go on stream gradually by early 2017. The specialty amines are especially used for the manufacturing of coatings, lubricants, crop protection products and pharmaceuticals. With this investment, BASF strengthens its worldwide amine production network with plants in Ludwigshafen and Schwarzheide, Germany, in Antwerp, Belgium, in Geismar, Louisiana and in Nanjing, China.
“This investment will allow us to meet the growing demand that our European customers have for specialty amines,” said Stefan Blank, President, BASF Intermediates division. “We have decades of experience in the development and manufacturing of amines and hold a leading position globally with regard to these versatile intermediate products. Through the current expansion, we will strengthen this position.”
In March and April 2014, BASF announced the construction of two new multiple product plants for the manufacturing of specialty amines at the BASF Verbund sites in Ludwigshafen, Germany and Nanjing, China, where startup is planned for 2015.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.